Orlando
,
USA
21 - 24 June 2024
American Diabetes Association (ADA 2024)
Presentation schedule and materials
Saturday, 22 June 2024
08:00
- 09:20
EDT
Publication
SELECT Trial—New Looks at Glycemia, Inflammation, and Heart Failure Scientific Session
Donna H Ryan1; Steven E Kahn2; Ildiko Lingvay3; Jorge Plutzky4
12:30
- 13:30
EDT
840-P
Publication
Efficacy and hypoglycemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1–5
Tina Vilsbøll1,2; Ariel Fu3; Monika Kellerer4; Bharath Kumar5; Stinne Byrholdt Søgaard3; Ronald Goldenberg6
12:30
- 13:30
EDT
842-P
Publication
Improvement in time in range after smart insulin pen initiation in Austria
Julia K Mader1; Niels Væver Hartvig2; Anne Kaas2; Rok Kosmina2; Yvonne Winhofer3
12:30
- 13:30
EDT
838-P
Publication
Impact of age on the efficacy and hypoglycemia outcomes of once-weekly insulin icodec versus once-daily insulin in T2D (ONWARDS 1–5)
André Vianna1; Julie Krogsdahl Bache2; Cyrus Desouza3; Mariana Fragao Marques2; Andrea Navarria2; Shehla Shaikh4; Ildiko Lingvay5
12:30
- 13:30
EDT
833-P
Publication
Understanding Attitudes about Basal Insulin: Insights from a Global Survey of People with Type 2 Diabetes
Simon Heller1; Ambika Gopalakrishnan (AG) Unnikrishnan2; Oktay Akkuş3; Sultan Linjawi4; Mansi J. Shah5
12:30
- 13:30
EDT
836-P
Publication
Adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive T2D: post hoc analysis of ONWARDS 5
Harpreet S. Bajaj1; Anders Meller Donatsky2; Susanne Engberg2; Johannes Handberg Juul Martiny2; André Vianna3; Ildiko Lingvay4
12:30
- 13:30
EDT
843-P
Publication
Multinational analysis of factors associated with missed bolus insulin injections using smart pen data
F Javier Ampudia-Blasco1,2; Maika Lindkvist Jensen3; Anne Kaas3; Rok Kosmina3; Rimei Nishimura4
12:30
- 13:30
EDT
1981-LB
Publication
Modeling the Impact of Semaglutide 2.4 mg in US Patients with Atherosclerotic Cardiovascular Disease and BMI ≥27 kg/m2
Mads Faurby1; Michael G. Nanna2; Joshua C. Toliver1; Quan V. Doan3; Alasdair D. Henry3; Thomas Scassellati Sforzolini3; Alina Levine3; Anthony Fabricatore2; Azadeh S. Houshmand-Øregaard2; Ann Marie Navar4
12:30
- 13:30
EDT
830-P
Publication
No evidence of increased physical activity-related hypoglycemia with once-weekly insulin icodec versus once-daily basal insulin in T2D: ONWARDS 1–5
Michael C Riddell1; Simon Heller2; Lisbeth Carstensen3; Thaís Machado Pagliaro Rocha3; Sara Kehlet Watt3; Vincent C Woo4
12:30
- 13:30
EDT
816-P
Publication
Health Care Resource Utilization and Costs with Timely vs. Delayed Basal Insulin Initiation
Liana K. Billings1; Sunny T. Sheth2; Brenna Brady3; Megan Richards3; Jigar R. Rajpura2; Joanna Mitri4,5
12:30
- 13:30
EDT
817-P
Publication
Demographic, Clinical, and Treatment Characteristics of Patients with Timely vs. Delayed Basal Insulin Initiation
Liana K. Billings1; Sunny T. Sheth2; Brenna Brady3; Megan Richards3; Jigar R. Rajpura2; Joanna Mitri4,5
12:30
- 13:30
EDT
824-P
Publication
No evidence of increased physical activity-related hypoglycemia with once-weekly insulin icodec versus once-daily basal insulin in T1D: ONWARDS 6
Harald Sourij1; Richard Bracken2; Lisbeth Carstensen3; Thaís Machado Pagliaro Rocha3; Sara Kehlet Watt3; Athena Philis-Tsimikas4
12:30
- 13:30
EDT
826-P
Publication
Efficacy and hypoglycemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with T2D by kidney function: ONWARDS 1–5
Peter Rossing1; Malik Benamar2; Alice Y.Y. Cheng3; Bharath Kumar4; Christian Laugesen2; Harpreet S. Bajaj5
12:30
- 13:30
EDT
841-P
Publication
Efficacy and hypoglycemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in T2D by ethnicity and race: ONWARDS 1–5
Ildiko Lingvay1; Julie Krogsdahl Bache2; Cyrus Desouza3; Mariana Fragão Marques2; Andrea Navarria2; André Vianna4
12:30
- 13:30
EDT
1884-LB
Publication
Real-world Impact of Once-weekly Injectable Semaglutide (sema OW) vs Sodium/Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Healthcare Resource Utilization (HCRU) Outcomes in Type 2 Diabetes (T2D): An Observational Study (PAUSE)
James Amamoo1; Riddhi Doshi2; Joshua Noone1; Lin Xie1; Cory Gamble1; Mico Guevarra1; Victoria Divino2; Justin Chen2; Aaron King3
12:30
- 13:30
EDT
1882-LB
Publication
Efficacy and hypoglycemia outcomes with once-weekly insulin icodec versus once-daily insulin degludec in T1D according to glycemic variability: ONWARDS 6 post hoc analysis
Concetta Irace1; Kamilla Begtrup2; Mariana Fragão Marques2; Sara Kehlet Watt2; David C Klonoff3
17:15
- 17:30
EDT
230-OR
Publication
Comparative Effectiveness of Semaglutide in Type 2 Diabetes-Year 2 Results of a Randomized Pragmatic Clinical Trial
John B. Buse1; Benjamin P. Soule2; Brian J. Harty3; Helene Nordahl Christensen4; Mark J. Cziraky5; Vincent J. Willey5; Simon Skibsted4
Sunday, 23 June 2024
12:30
- 13:30
EDT
1101-P
Publication
Patient-centered weight management clinical decision support: A proof-of-concept study
Jessica L. Schwartz1; Erik Almazan1; Kelly Olsson2; Kimberly Gudzune1,3
12:30
- 13:30
EDT
766-P
Publication
Long-Term Effectiveness Associated With Maintenance Doses of Once-Weekly Semaglutide in US Adults With Poorly Controlled T2D
Xi Tan1; Yiwen Cao1; Tyler J. Dunn1; Yuanjie Liang1; Joshua Noone1; Cory L. Gamble1; Aaron A. King2
12:30
- 13:30
EDT
763-P
Publication
CagriSema improves insulin sensitivity in diet-induced obese rats
Anna Secher1; Christian Lehn Brand1; Kirsten Raun1
12:30
EDT
774-P
Publication
Impact of Newer GLP-1 RAs on HbA1c in US Adults With Type 2 Diabetes: A Population-Level Time-Series Analysis
Lei Lv1; Yan Wang2; Lin Xie1; Josh Noone1; Sara Alvarez1; Yuehan Zhang3; Yan Song4; Daniel M. Rotroff5
12:30
- 13:30
EDT
752-P
Publication
Evaluating the efficacy of oral semaglutide in Chinese patients with T2D by baseline characteristics: post hoc analysis of PIONEER 11 and 12
Linong Ji1; Guoyue Yuan2; Jun Liu3; Bingjie Zhang4; Wenyan Liu4; Zewei Shen4
12:30
- 13:30
EDT
857-P
Publication
Real-world Impact of Once-weekly Injectable Semaglutide on Weight, BMI and HbA1c Outcomes in Type 2 Diabetes: An Observational Study (PAUSE)
James Amamoo1; Riddhi Doshi2; Joshua Noone1; Lin Xie1; Cory Gamble1; Mico Guevarra1; Victoria Divino2; Justin Chen2; Aaron King3
12:30
- 13:30
EDT
784-P
Publication
Semaglutide in people with peripheral artery disease and type 2 diabetes: baseline comorbidities and concomitant medications from the STRIDE trial
Neda Rasouli1; Andrei-Mircea Catarig2; Yasemin Hansen2; Kim Houlind3; Chethana Kalmady Ramesh4; Bernhard Ludvik5; Joakim Nordanstig6; Harald Sourij7; Subodh Verma8; Marc Bonaca9
16:45
- 17:00
EDT
763-P
Publication
STEP-HFpEF-DM—A Deep Dive into the Metabolic Outcomes
Melanie J Davies1
23:30
EDT
740-P
Publication
Persistence and Adherence of Once-Weekly GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in a Real-World Setting
Tyler J. Dunn1; Yong Zhu2; Noelle N. Gronroos2; Lin Xie1; Josh Noone1; Andrew Sargent2; Liana K. Billings3
Monday, 24 June 2024
12:30
- 13:30
EDT
1692-P
Publication
Prevalence, Characteristics, and Clinical Burden Among Patients with Overweight or Obesity and Established ASCVD in a US Real World Setting
Wojciech Michalak1; Nana Boame2; Xin Zhao2; Neil Lamarre2; Andrew Rava2; Quan V. Doan2; Mads Faurby1; Bríain Ó Hartaigh1; Anthony Fabricatore1; Zhenxiang Zhao1
12:30
- 13:30
EDT
1691-P
Publication
Changes in Body Weight in Patients with Obesity or Overweight Treated with Semaglutide 2.4 mg, or not Treated with Anti-obesity Medication: A Real-World Retrospective Cohort Study in the United States (SCOPE 2)
Wojciech Michalak1; Anthony Fabricatore1; Briain O Hartaigh1; Aleksandrina Ruseva1; Zhenxiang Zhao1; Devika Umashanker2
12:30
- 13:30
EDT
1684-P
Publication
CONCRETE – Characterization of Patients Receiving Telemedicine and Branded Antiobesity Medication for Medical Weight Management: A Retrospective Analysis
Alpana Shukla1; David Li1; Anthony Casper1; Louis Aronne1; Debra D’Angelo1; Katherine H. Saunders1,2; Leon Igel1,2; Eugene Lucas1; Kathya Palepu1; Emily Zacherle3; Andrea Traina3; Kelly Olsson3
13:30
- 14:40
EDT
Publication
The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist—Once-Weekly Semaglutide and the FLOW Trial Results: Scientific Session
Peter Rossing1; Richard Pratley2; Vlado Perkovic3; Kenneth Mahaffey4; Johannes Mann5,6; Katherine Tuttle7,8
Keywords